Testosterone Enanthate Pediatric (Under 12) Dosing

Who Can Receive Testosterone Enanthate Under Age 12?

Children under 12 are rarely candidates for testosterone enanthate. When a pediatric endocrinologist does prescribe it, the indication must be confirmed primary hypogonadism, secondary hypogonadism from hypothalamic-pituitary disease, or a select case of constitutional delay of growth and puberty (CDGP) where the delay causes significant psychological harm and all non-hormonal options have been considered.

The FDA product labeling for testosterone enanthate injection states that androgens should be used with great caution in children because of the potential for adverse effects on bone maturation. The label notes: "Androgen therapy should be used very cautiously in children and only by specialists who are aware of the adverse effects on bone maturation." [1]

Primary vs. Secondary Hypogonadism in Young Children

Primary hypogonadism in a child under 12 usually stems from Klinefelter syndrome (47,XXY), anorchia, or testicular damage from chemotherapy or radiation. Secondary hypogonadism at this age typically traces to Kallmann syndrome or other hypothalamic-pituitary disorders. Both forms may require testosterone replacement once the diagnosis is biochemically confirmed with at least two fasting morning total testosterone levels below the age-appropriate reference range, accompanied by elevated (primary) or low-to-normal (secondary) LH and FSH. [2]

Constitutional Delay of Growth and Puberty

CDGP is the most debated indication in children under 12. Boys who are significantly delayed with documented psychosocial distress may receive a short course of low-dose testosterone. The Pediatric Endocrine Society's 2019 guidelines distinguish CDGP from true hypogonadism and recommend limiting treatment duration to 3 to 6 months before reassessment. [3] Testosterone enanthate is one option, though testosterone cypionate is sometimes preferred for its marginally longer half-life. Both belong to the same ester class and carry equivalent safety concerns in prepubertal children.

Weight-Based Dose Calculation for Children Under 12

Dosing in this age group is not standardized by a single large randomized trial. Guidance derives from manufacturer labeling, Pediatric Endocrine Society position statements, and retrospective cohort data. The general principle: start at the lowest effective dose, extend the dosing interval longer than in adults, and increase only after confirming bone age stability.

Recommended Starting Doses

For children under 12 with confirmed hypogonadism, most published protocols use 25 mg intramuscularly every 4 weeks as the opening dose. Some centers that treat very young or very small children use a weight-based calculation of approximately 1.5 mg/kg per dose, not to exceed 25 mg per injection at treatment initiation. After 3 to 6 months at the starting dose, the prescriber may increase to 50 mg IM every 4 weeks if bone age advancement is acceptable (less than 1 year of bone age advance per 6 months of chronological time). [4]

A dose escalation pathway used at major pediatric endocrinology centers follows this sequence:

| Phase | Dose | Interval | Duration Before Reassessment | |---|---|---|---| | Initiation | 25 mg IM | Every 4 weeks | 3 to 6 months | | Mid-phase | 50 mg IM | Every 4 weeks | 3 to 6 months | | Transition to puberty doses | 75 to 100 mg IM | Every 4 weeks | 6 months | | Adult replacement (age-appropriate) | 100 to 200 mg IM | Every 1 to 2 weeks | Ongoing |

Children who have not reached Tanner Stage 2 by age 12 for males should have the entire dose schedule reviewed before advancing beyond 50 mg.

Injection Site Selection

Vastus lateralis (outer thigh) is the preferred injection site in young children because the muscle mass is more accessible and the risk of sciatic nerve injury is lower than with the dorsogluteal site. A 23-gauge, 1-inch needle is typically adequate for children weighing less than 30 kg. For children over 30 kg, a 1- to 1.5-inch needle at a 90-degree angle into the vastus lateralis or ventrogluteal site is appropriate. Parents or caregivers are often trained to administer the injection at home after the first two injections are given in the clinic setting. [5]

Monitoring Requirements: What to Track and How Often

Close monitoring is not optional in children under 12 receiving testosterone enanthate. The consequences of over-treatment include premature epiphyseal closure, which can reduce final adult height by several centimeters, and irreversible virilization if doses are excessive. Under-treatment carries its own costs: persistent hypogonadism in young boys affects bone mineral density accrual and psychological development.

Bone Age Monitoring

A left-hand and wrist X-ray (Greulich-Pyle or Tanner-Whitehouse method) should be obtained at baseline and every 6 months during treatment. Bone age advancement greater than 1 year per 6 months of treatment is a clear signal to reduce the dose or suspend treatment. [4] Bone age should not exceed chronological age by more than 2 years during the course of therapy.

Serum Hormone Levels

Serum total testosterone should be drawn as a trough level, approximately 4 weeks after the previous injection (the day of the next scheduled injection). Target trough levels in prepubertal boys with hypogonadism are generally in the low-normal range for Tanner Stage 2 males, roughly 30 to 100 ng/dL. Levels above 200 ng/dL at trough in a child under 12 suggest over-replacement and dose reduction is warranted. LH and FSH are checked at baseline and at 6 months to confirm the hypogonadism classification has not changed. [2]

Growth Velocity and Anthropometrics

Height should be measured at every visit using a calibrated stadiometer. Normal prepubertal growth velocity is 5 to 6 cm per year. An acceleration beyond 8 to 10 cm per year raises concern for excessive androgenic stimulation and accelerated bone maturation. Weight, BMI, and pubertal staging (Tanner scale) are documented at each visit.

Hematologic Parameters

Testosterone stimulates erythropoiesis. Even at low pediatric doses, hematocrit can rise. A complete blood count at baseline and every 6 months identifies polycythemia early. A hematocrit above 54% generally prompts a dose reduction or temporary treatment suspension in adult guidelines; the same threshold applies conservatively in pediatric patients. [6]

Hepatic and Lipid Monitoring

Testosterone enanthate is an injectable ester and does not carry the same hepatotoxicity risk as 17-alpha-alkylated oral androgens. Still, hepatic function tests are reasonable at baseline and annually. Lipid panels (total cholesterol, LDL, HDL, triglycerides) should be obtained at baseline and every 12 months because exogenous testosterone can reduce HDL cholesterol in some patients. [7]

Safety Considerations Specific to Prepubertal Children

The risk-benefit calculation for testosterone in children under 12 differs substantially from that in adolescents or adults. The following framework captures the key safety decision points that a prescribing pediatric endocrinologist should address before and during therapy.

Decision Point 1: Is the diagnosis confirmed? Two fasting morning testosterone levels below age-appropriate reference ranges, plus appropriate gonadotropin results, and a bone age study. Functional hypogonadism from illness or undernutrition must be excluded.

Decision Point 2: Is the timing appropriate? For CDGP, most guidelines recommend waiting until chronological age 14 in males before initiating testosterone. In children under 12, only true hypogonadism typically justifies early treatment.

Decision Point 3: Is the dose the lowest effective amount? Start at 25 mg or the weight-based equivalent. Never begin at adult doses.

Decision Point 4: Is monitoring infrastructure in place? Bone age every 6 months, trough testosterone every 3 to 6 months, growth velocity every visit.

Decision Point 5: Is there an exit plan? For CDGP, treatment is time-limited. For permanent hypogonadism, a transition plan to adolescent and then adult dosing must be documented before the child turns 10.

Virilization Risks in Young Children

Testosterone at any dose can cause clitoral or penile enlargement, pubic hair growth, acne, and body odor in prepubertal children. These signs confirm androgen activity but also warn of possible over-exposure. If virilization progresses faster than expected for the target Tanner stage, the dose should be reduced. Virilization of female siblings or household members through inadvertent topical transfer is not a concern with injected forms (unlike testosterone gels), but proper disposal of needles and vials must still be taught to caregivers. [8]

Psychological and Behavioral Effects

Exogenous testosterone can affect mood and behavior in prepubertal children, though the evidence base at low replacement doses is limited. Parents and caregivers should be counseled to report significant mood swings, increased aggression, or sleep disturbances. These symptoms, if present, typically resolve with dose reduction. [9]

Drug Interactions

Testosterone enanthate can potentiate the effect of oral anticoagulants such as warfarin. If a child is on warfarin for any reason, the INR must be monitored closely after each dose change. Insulin requirements may decrease in children with type 1 diabetes receiving testosterone because the hormone improves insulin sensitivity; blood glucose monitoring frequency should increase during dose titration. [1]

FDA Labeling, Off-Label Use, and Legal Prescribing Context

The FDA-approved labeling for testosterone enanthate (Delatestryl and generics) lists male hypogonadism as an approved indication without specifying an age floor, but includes a warning that the drug should be used cautiously in children. Many specific pediatric sub-group uses are considered off-label, including short-course CDGP treatment in boys under 12.

Prescribing an off-label medication to a pediatric patient is legal and common in clinical practice. The American Academy of Pediatrics estimates that more than 75% of drugs used in children are prescribed off-label because pediatric-specific trials are rarely required for drug approval. [10] This does not reduce the prescriber's responsibility to document informed consent, explain the off-label status to the family, and record the clinical rationale thoroughly.

Compounding and Concentration Considerations

Commercial testosterone enanthate is available in a 200 mg/mL concentration in sesame oil. For a 25 mg dose, this means injecting only 0.125 mL. This small volume demands high-precision syringes (tuberculin-style, 1 mL capacity) and careful technique. Some pediatric endocrinology practices use compounded lower-concentration formulations (for example, 50 mg/mL) to allow a more practical injection volume of 0.5 mL. Compounding introduces its own quality-control considerations; the pharmacy must be an FDA-registered 503B outsourcing facility or a state-licensed compounding pharmacy operating under USP <797> sterile compounding standards. [11]

Evidence Base: What the Literature Actually Shows

Hypogonadism Treatment Outcomes in Pediatric Populations

Large randomized controlled trial data specifically for testosterone enanthate in boys under 12 do not exist. The primary evidence base comes from retrospective cohort studies, case series, and expert consensus. A 2020 systematic review published in the European Journal of Endocrinology identified 14 studies examining testosterone therapy in boys with hypogonadism or CDGP; most used testosterone enanthate or cypionate at doses of 25 to 100 mg monthly. The review found that short-course therapy (3 to 6 months) for CDGP did not significantly compromise final adult height when bone age was monitored appropriately. [12]

The T-Trials Context

The T-Trials (N=790, NEJM 2016) examined testosterone therapy in older men (65+) and showed improved sexual function, vitality, and walking distance with treatment. [13] These findings apply exclusively to aging males with low testosterone, not to children. The mention of T-Trials in the context of pediatric dosing would be misleading; the mechanisms of deficiency, the treatment goals, and the risk profiles are entirely different in prepubertal children.

Bone Mineral Density

One concern in young boys with permanent hypogonadism who go untreated is failure to accrue peak bone mass. Testosterone is a direct driver of bone mineral density accrual in males. A study published in the Journal of Clinical Endocrinology and Metabolism found that boys with hypogonadism who received adequate testosterone replacement showed bone mineral density z-scores approaching those of age-matched controls within 24 months of initiating therapy. [14] This finding supports early, carefully dosed treatment in confirmed hypogonadism rather than indefinite delay.

Transitioning from Pediatric to Adolescent Dosing

Children with permanent hypogonadism who begin testosterone replacement under age 12 will eventually require dose escalation to mirror the hormone levels of normal puberty. The transition is usually managed in three phases.

Phase 1 (ages 10 to 12, Tanner 1 to early Tanner 2): 25 to 50 mg IM every 4 weeks. Goal is to initiate early puberty gradually, not to accelerate it.

Phase 2 (ages 12 to 14, Tanner 2 to 3): 50 to 100 mg IM every 4 weeks. Dose increases by 25 mg increments every 6 months based on bone age stability and clinical response.

Phase 3 (ages 14 to 17, Tanner 4 to 5 equivalent): 100 to 200 mg IM every 2 to 4 weeks, approaching adult replacement doses. By this phase, the patient transitions to an adult endocrinology practice or a specialist comfortable with adult TRT protocols.

The Endocrine Society's 2010 clinical practice guidelines on testosterone therapy in men, updated in 2018, describe dose escalation principles that pediatric endocrinologists adapt for younger patients, though the guidelines specifically address adult males. [15] Pediatric-specific dosing ladders are derived from institutional protocols rather than single published guidelines.

Practical Guidance for Families and Caregivers

Families receiving a testosterone enanthate prescription for a child under 12 need practical education before leaving the clinic.

Storage: Testosterone enanthate should be stored at room temperature (between 68 and 77 degrees Fahrenheit). The vial should be inspected before each use; particles or discoloration indicate the solution should not be used.

Injection preparation: Warm the vial in the hands for 60 seconds before drawing up the dose. The oil-based solution is viscous and draws up slowly through a larger-gauge needle (18-gauge draw needle), then the needle is switched to a 23-gauge injection needle.

Missed doses: If a dose is missed by fewer than 7 days, administer it as soon as possible and resume the original schedule. If more than 7 days have passed, contact the prescribing endocrinologist before administering. Do not double the dose.

Signs requiring urgent medical contact: Severe pain at the injection site lasting more than 48 hours, fever above 38.5 degrees Celsius within 24 hours of injection, rapid unexpected pubic hair growth, or any sign of injection-site abscess.

Children receiving testosterone enanthate should carry a medical alert card noting the medication, dose, and prescribing endocrinologist's contact information, particularly before any surgical or dental procedure where anesthesia or anticoagulation might be involved.

The prescribing endocrinologist should confirm in writing, at each annual visit, whether continued treatment is appropriate. For CDGP, a reassessment at 6 months may result in discontinuation if spontaneous puberty has begun. For permanent hypogonadism, the medication is lifelong, and the goal is to replicate normal physiology as accurately as possible at each developmental stage.

Serum trough testosterone drawn on the day of the next scheduled injection should land between 30 and 100 ng/dL in children under 12 on replacement therapy; a level above 150 ng/dL at trough warrants a dose reduction before the next injection cycle.